Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Damora Therapeutics, Inc. (DMRA)

Damora Therapeutics moves incorporation from Delaware to Cayman Islands

Neutral Impact 3 of 5 shareholder Written later

Damora Therapeutics completed its redomestication from Delaware to the Cayman Islands, effective July 16, 2026, after stockholders approved it at a February 9, 2026 special meeting. The company says the move does not change its business, management, obligations, assets or liabilities, and its shares continue to trade on Nasdaq under the symbol DMRA, now under a new CUSIP. The filing states that certain shareholder rights changed as a result, so holders should review the Cayman articles.

Key points

  • Redomestication effective July 16, 2026; stockholders approved it at a February 9, 2026 special meeting.
  • Ordinary shares began trading under new CUSIP G2646Y104 at the open on July 20, 2026; Nasdaq symbol remains DMRA.
  • Cayman memorandum and articles of association now govern the company in place of its Delaware charter and bylaws; certain shareholder rights changed.
  • Directors and executive officers entered into new indemnification agreements on July 16, 2026.

The filing

CompanyDamora Therapeutics, Inc. (DMRA)
Form8-K, current report
Filed with the SECJul 20, 2026, 4:00 PM ET
Accession number0001193125-26-308899

Items reported: 1.01 Material Definitive Agreement3.03 Change to Shareholder Rights5.03 Bylaw / Charter Amendment7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 20, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.